Pfizer to Host Analyst Meeting on July 28th to Review Neuroscience Pipeline and Platform

NEW YORK, Jul 14, 2008 (BUSINESS WIRE) -- Pfizer, Inc announced today that it will present nine abstracts
from its Alzheimer's disease (AD) research and development program,
including three on the two promising investigational therapies in the
early stages of development, at the 2008 Alzheimer's Association
International Conference on Alzheimer's Disease (ICAD) in Chicago,
July 26-31.

Pfizer will also host an analyst briefing at ICAD to review its
neuroscience pipeline and platform on Monday, July 28. In addition,
Pfizer will sponsor a satellite symposium, "Innovative Approaches to
Alzheimer's Disease: Developing the Next Generation of Treatment," on
Tuesday, July 29.

"With the expected huge increase in the incidence of Alzheimer's
disease worldwide in the next 25 years, Pfizer's neuroscience team has
made this devastating illness our highest priority," said Dr. Liam
Ratcliffe, senior vice president and development head for Pfizer
Neuroscience. "With new insights into the underlying causes of
Alzheimer's discovered in only the past few years, our scientists are
working to develop new medicines that improve memory and other
cognitive function, and importantly halt or significantly slow the
progression of the disease. We are also working on approaches that
could lead to earlier and better diagnosis."

Pfizer's investigational compounds target multiple pathways to
combat AD, beta amyloid, the harmful protein that builds up in the
brains of AD patients; amyloid plaques, the sticky deposits made of
beta amyloid fragments that impair the function of brain cells;
chronic inflammation of neurons, and loss of function across the
synapses (or gaps) between neurons.

Data from Pfizer to be presented at the meeting include:

-- Receptor for Advanced Glycation End-products (RAGE) Antagonist:
   Pfizer is in collaboration with TransTech Pharma to develop and
   commercialize a portfolio of RAGE modulators. RAGE is a
   cell-surface receptor that may play a key role in multiple aspects
   of AD. Targeting RAGE for Alzheimer's is a novel approach and
   Pfizer is pioneering this approach in the clinic.

   -- Initial Phase II data on the safety and tolerability of Pfizer's
      oral RAGE antagonist known as PF-04494700 will be presented by
      Dr. Marwan Sabbagh, FAAN, director of The Cleo Roberts Center of
      Clinical Research at the Sun Health Research Institute in Sun
      City, AZ, on Wednesday, July 30th at 12:30 p.m. CST.

   -- Preclinical data on the effect of PF-04494700 on chronic
      inflammation and buildup of amyloid plaques - two abnormal
      processes that are implicated in causing damage and death to
      brain cells in AD - will also be presented by Dr. Jeffrey
      Webster of TransTech Pharma on Monday, July 28th at 12:30 p.m.
      CST.

-- Humanized Anti-Amyloid Monoclonal Antibody: Preclinical data on the
   effect of PF-04360365, Pfizer's investigational monoclonal antibody
   in Phase 1 trials, on beta amyloid levels in the brains of mice
   will be presented by Dr. Thomas Lanz, Senior Scientist at Pfizer,
   on Monday, July 28th at 12:30 p.m. CST. Monoclonal antibodies are
   designed to selectively target a specific protein, which, in the
   case of AD, is beta amyloid.

Additional Preclinical Research: Pfizer will also present data on
a potential blood biomarker that could help in identifying patients
with AD; two studies on the role of the brain's immune system in the
formation of amyloid plaques; a potential method of using novel
imaging and microscopic analysis to quantify AD neuropathology, and
early research on an additional investigational Pfizer compound on the
inhibition of an enzyme in the brain.

About Alzheimer's Disease

Alzheimer's disease is a progressive disorder characterized by the
gradual loss of memory and a decline in cognitive ability; changes in
behavior, and a loss in ability to carry out daily activities. It
places a tremendous burden on patients, those caring for them, and
healthcare systems, costing the U.S. Government more than $148 billion
annually. Alzheimer's disease remains one of the world's most
undiagnosed diseases, with only one-third of the world's approximately
18 million sufferers receiving treatment.

DISCLOSURE NOTICE: The information contained in this release is as
of July 14, 2008. Pfizer assumes no obligation to update any
forward-looking statements contained in this release as the result of
new information or future events or developments.

This release contains forward-looking information about certain
investigational compounds, including their potential benefits in
treating Alzheimer's disease, that involves substantial risks and
uncertainties. Such risks and uncertainties include, among other
things, the uncertainties inherent in research and development;
decisions by regulatory authorities regarding whether and when to
approve any drug applications that may be filed for any such compounds
as well as their decisions regarding labeling and other matters that
could affect their availability or commercial potential; and
competitive developments.

A further description of risks and uncertainties can be found in
Pfizer's Annual Report on Form 10-K for the fiscal year ended December
31, 2007 and in its reports on Form 10-Q and Form 8-K.

SOURCE: Pfizer, Inc

Pfizer, Inc
Media:
Shreya Jani, 212-733-4889
shreya.jani@pfizer.com
or
Liz Power, 860-732-4987
elizabeth.power@pfizer.com
or
Investor:
Jennifer Davis, 212-733-0717

Copyright Business Wire 2008